In addition to contrast-enhanced mammography (CEM) demonstrating over a 90 percent detection rate for multifocal masses, researchers found that no significant difference between histological measurements and CEM, according to study findings presented at the European Congress of Radiology.

In a recent interview, Emily Conant, M.D., discussed findings from two studies presented at the European Congress of Radiology (ECR) conference that showed the potential impact of image-based AI risk models and breast arterial calcification detection in mammography screening.

The updated software reportedly enables a threefold improvement in MRI scan time and enhanced image sharpness.

Offering an array of AI-powered automation and image optimization, the new Elevate software is geared to maximizing workflow efficiencies for the EPIQ Elite and Affiniti ultrasound systems.

18F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.

In a video interview from the International Stroke Conference (ISC), Jeremy Heit, M.D., Ph.D., discussed new research revealing over 90 percent sensitivity and specificity rates for AI detection of subdural hematomas on non-contrast-enhanced head CTs.

The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).

Designed for advanced OB-GYN applications, the Samsung Z20 ultrasound platform reportedly provides a combination of artificial intelligence (AI) tools and enhanced ergonomics.

In the third part of a three-part interview from the recent RSNA conference, Mark Traill, M.D., discusses the potential of image-based risk assessment artificial intelligence (AI) algorithms in bolstering adherence to screening protocols for women at high risk for breast cancer.

Catch up on emerging research from the recent 2024 Radiological Society of North America (RSNA) conference.

Catch up on video interviews from the recent 2024 Radiological Society of North America (RSNA) conference.

In the second part of a three-part interview from the recent RSNA conference, Mark Traill, M.D., emphasizes patience and monitoring with the assessment of AI to ensure optimal use of the technology to help ease the strain of increasing breast imaging volume.

Catch up on the top radiology content of the past week.

In the first of a three-part interview from the recent RSNA conference, Mark Traill, M.D., discusses current challenges in breast radiology and the potential of AI to help mitigate some of these issues.

In a recent interview at the RSNA conference, Raj Chopra, MD shared his insights on the continued rise of cyberattacks, the impact of these attacks in radiology and keys to prevention and effectively responding to such events.

New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.

In an interview at the RSNA conference, Sundus Lateef, MD, discussed the rise of silicosis and associated CT findings in a recent study of engineered stone countertop workers.

In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.

Emerging research from the RSNA conference suggests that two-dimensional mammography would only detect 41 percent of detectable breast cancer.

In a recent interview, Sarah Friedewald, MD, discussed new study findings for an adjunctive AI software for digital breast tomosynthesis (DBT) that revealed nearly equivalent sensitivity and specificity rates for breast cancer across a diverse cohort.